---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-012810"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T13:49:57.470106+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Editas Q2 net loss $40.3M ($0.56/sh); cash $480M; EDIT-301 on track for 20 patients by year-end

## Summary
- Net loss $40.3M ($0.56 per share) vs. $53.5M ($0.78) in Q2 2022.
- Cash, cash equivalents and marketable securities $480.0M as of June 30, 2023.
- EDIT-301 RUBY trial (SCD) on track to dose 20 total patients; clinical update by year-end.
- EDIT-301 EDITHAL trial (TDT) commenced parallel dosing; update expected by year-end.
- Erick Lucera appointed CFO and Linda C. Burkly, Ph.D. appointed CSO.

## SEC filing metadata
- accession: 0001558370-23-012810
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000155837023012810/0001558370-23-012810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000155837023012810/edit-20230802x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-012810
- JSON: https://secwatch.observer/filing/0001558370-23-012810.json
- Plain text: https://secwatch.observer/filing/0001558370-23-012810.txt

## Key facts
- Earnings Releases
  Editas Medicine, Inc. reported second quarter 2023 results: net income $40.3 million, EPS $0.56 per share.
  - Period: second quarter 2023
  - Net income: $40.3 million
  - EPS: $0.56 per share
  - Result: reported results
  source text: For the three months ended June 30, 2023, net loss attributable to common stockholders was $40.3 million, or $0.56 per share, compared to net loss of $53.5 million, or $0.78 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1650664/000155837023012810/0001558370-23-012810-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.